Implementing a Polypill Approach in Heart Failure: A Survey Study-Reference-Cited by-同舟云学术

Implementing a Polypill Approach in Heart Failure: A Survey Study

Published:2024-04-09 Issue: Volume:3 Page:
ISSN:2754-0650
Container-title:Journal of Asian Pacific Society of Cardiology
language:en
Short-container-title:J Asian Pac Soc Cardiol

Author:

Shariff Raja Ezman Raja¹^ORCID,Ibrahim Khairul Shafiq¹^ORCID,Kasim Sazzli¹^ORCID

Affiliation:

1. Universiti Teknologi MARA Sungai Buloh, Jalan Hospital, Selangor, Malaysia

Abstract

This survey study aimed to assess readiness, amongst cardiologists and cardiology trainees, in using a polypill strategy in the management of heart failure. A national-level, 21-item survey study was conducted between 1 January 2023 and 30 June 2023. A total of 120 participants responded, with clinical practice differing greatly. Potential challenges in polypill prescription were mainly surrounding clinical safety and cost. Dosing strategies were also an important aspect, many believing that polypills should exist with various dosing combinations. In addition, evidence focused on safety and tolerability were felt important, pre-marketing. This survey demonstrates how implementation of a polypill strategy may remain challenging, especially in an Asia-Pacific community.

Publisher

Radcliffe Media Media Ltd

Reference8 articles.

1. Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 2018;72:351–66. https://doi.org/10.1016/j.jacc.2018.04.070; PMID: 30025570.

2. Teng T-HK, Tromp J, Tay WT, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health 2018;6:e1008–18. https://doi.org/10.1016/S2214-109X(18)30306-1; PMID: 30103979.

3. Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387:967–77. https://doi.org/10.1056/NEJMoa2208275; PMID: 36018037.

4. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability, and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022;400:1938–52. https://doi.org/10.1016/S0140-6736(22)02076-1; PMID: 36356631.

5. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–200. https://doi.org/10.1093/eurheartj/ehw128; PMID: 27206819.